Arcoma AB (OSTO:ARCOMA) ROCE %: 5.57% (As of Mar. 2026)


OSTO:ARCOMA Arcoma AB OSTO:ARCOMA
75 GF Score
Price kr8.80
GF Value kr7.85
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcoma AB ROCE %?

Arcoma AB OSTO:ARCOMA +3.53% 75 ROCE % is 5.57% as of Mar. 2026. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.85 (Modestly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arcoma AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.57%.

Arcoma AB  (OSTO:ARCOMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arcoma AB ROCE % Related Terms

Arcoma AB ROCE % Historical Data

* Premium members only.

The historical data trend for Arcoma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcoma AB ROCE % Chart

Arcoma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.56 6.28 8.99 25.48 9.58

Arcoma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.32 0.23 12.00 9.47 5.57
OSTO:ARCOMA
75GF Score
Arcoma AB OSTO:ARCOMA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcoma AB ROCE % Calculation

Arcoma AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=6.424/( ( (80.463 - 21.129) + (96.651 - 21.924) )/ 2 )
=6.424/( (59.334+74.727)/ 2 )
=6.424/67.0305
=9.58 %

Arcoma AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=4.184/( ( (96.651 - 21.924) + (101.842 - 26.304) )/ 2 )
=4.184/( ( 74.727 + 75.538 )/ 2 )
=4.184/75.1325
=5.57 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.57% mean?
Arcoma AB (OSTO:ARCOMA) has a ROCE % of 5.57% as of Mar. 2026.
Is Arcoma AB's ROCE % too high?
Arcoma AB's current ROCE % is 5.57%. The Medical Devices & Instruments industry median ROCE % is 2.23. Arcoma AB's value of 5.57% is 149.8% above this industry median. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's ROCE % compare to ABT and SYK?
Arcoma AB's ROCE % of 5.57% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Arcoma AB's value of 5.57% is 149.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current ROCE % of 5.57% is 149.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current ROCE % is 5.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Modestly Overvalued. The stock's GF Value™ is kr7.85, compared to a current price of kr8.80 — trading 12.1% above its estimated fair value. The current ROCE % is 5.57% and 149.8% above the Medical Devices & Instruments industry median of 2.23. Arcoma AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current ROCE % is 5.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?

Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued. The current stock price of kr8.80 is trading 12.1% above its estimated GF Value™ of kr7.85. GuruFocus considers Arcoma AB to be Modestly Overvalued.

Key valuation signals for OSTO:ARCOMA:

  • ROCE %: 5.57%
  • GF Value™: kr7.85 vs. price of kr8.80 (12.1% above fair value)
  • GF Score™: 75/100 with 4 warning signs
  • Industry Position: 149.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcoma AB Business Description

Address Annavagen 1, Vaxjo, SWE, SE-352 46
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score

Get the complete analysis for OSTO:ARCOMA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.80
Price
kr7.85
GF Value